Skip to main content

BriaCell Therapeutics Corp.

BCTX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001610820

No open-market purchases or sales by BriaCell Therapeutics Corp. insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $1.58M in total; no superinvestor holds it.

Other share classesBCTXLBCTXZ

13F holders, Q1 2021

Institutional positions in BriaCell Therapeutics Corp. as of Mar 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
10
No complete 13F data for Q4 2020
Shares held
375.2K
No complete 13F data for Q4 2020
Total value
$1.45M
No complete 13F data for Q4 2020

Holders and value by quarter

Institutions reporting BCTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ1 2021: 10 institutions
Q1 2021: 10 institutionsQ2 2021: 24 institutionsQ3 2021: 21 institutionsQ4 2021: 20 institutionsQ1 2022: 18 institutionsQ2 2022: 22 institutionsQ3 2022: 22 institutionsQ4 2022: 21 institutionsQ1 2023: 21 institutionsQ2 2023: 21 institutionsQ3 2023: 21 institutionsQ4 2023: 26 institutionsQ1 2024: 20 institutionsQ2 2024: 20 institutionsQ3 2024: 22 institutionsQ4 2024: 26 institutionsQ1 2025: 14 institutionsQ2 2025: 16 institutionsQ3 2025: 13 institutionsQ4 2025: 13 institutionsQ1 2026: 16 institutionsQ2 2026: 19 institutions
Value heldQ1 2021: $1.45M
Q1 2021: $1.45MQ2 2021: $20.3MQ3 2021: $4.77MQ4 2021: $10.9MQ1 2022: $33.5MQ2 2022: $17.0MQ3 2022: $14.3MQ4 2022: $12.3MQ1 2023: $19.4MQ2 2023: $17.9MQ3 2023: $17.0MQ4 2023: $14.6MQ1 2024: $6.38MQ2 2024: $452.0KQ3 2024: $538.1KQ4 2024: $379.1KQ1 2025: $94.1KQ2 2025: $181.1KQ3 2025: $136.5KQ4 2025: $69.2KQ1 2026: $1.62MQ2 2026: $1.58M
Institutions holding BCTX and their total value by quarter
QuarterHoldersValue
Q2 202619$1.58M
Q1 202616$1.62M
Q4 202513$69.2K
Q3 202513$136.5K
Q2 202516$181.1K
Q1 202514$94.1K
Q4 202426$379.1K
Q3 202422$538.1K
Q2 202420$452.0K
Q1 202420$6.38M
Q4 202326$14.6M
Q3 202321$17.0M
Q2 202321$17.9M
Q1 202321$19.4M
Q4 202221$12.3M
Q3 202222$14.3M
Q2 202222$17.0M
Q1 202218$33.5M
Q4 202120$10.9M
Q3 202121$4.77M
Q2 202124$20.3M
Q1 202110$1.45M

Institutions, Q1 2021

Shares, value and share of portfolio for each institution holding BriaCell Therapeutics Corp..

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.

Institutions holding BCTX in Q1 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Sabby Management, LLC160,182$618.0K0.45%––
Redmond Asset Management, LLC131,731$508.0K0.16%––
Zeke Capital Advisors, LLC45,000$174.0K0.01%––
Eqis Capital Management, Inc.16,339$63.0K0.00%––
Virtu Financial LLC15,121$58.0K0.00%––
Advisor Group Holdings, Inc.6,012$23.0K0.00%––
UBS Group AG632$2.00K0.00%––
Harbour Investments, Inc.165$1.00K0.00%––
Toronto Dominion Bank12$00.00%––
Royal Bank of Canada17$00.00%––